These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38143039)

  • 1. The availability of fentanyl test strips in Georgia community pharmacies.
    Rawal S; Khail JW; Stone RH; Young HN
    J Am Pharm Assoc (2003); 2024; 64(2):524-529.e1. PubMed ID: 38143039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alabama community pharmacists' knowledge and perceptions regarding fentanyl test strips: A cross-sectional survey.
    Woods S; Blythe E; Valle-Ramos G; Richardson J; Pham K; Diggs K; Harris K; Zhao Y; Hohmann L
    J Am Pharm Assoc (2003); 2024 Jun; ():102148. PubMed ID: 38914293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. North Carolina pharmacists' willingness to sell fentanyl test strips: a survey study.
    Marley GT; Ostrach B; Carpenter D
    Harm Reduct J; 2023 Jan; 20(1):10. PubMed ID: 36694186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of naloxone availability in Georgia community pharmacies.
    Stone RH; Hur S; Young HN
    J Am Pharm Assoc (2003); 2020; 60(2):357-361. PubMed ID: 31866387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survey of Georgia community pharmacists' needs to engage in advanced community pharmacy services.
    Hazelett KG; Keedy C; Fraley AD; Bazel K; Crosby J; Johnson BR
    J Am Pharm Assoc (2003); 2024; 64(2):517-523.e2. PubMed ID: 38097176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are pharmacists' knowledge and practice the key to promoting deprescribing of potentially inappropriate medication: a missing link between treatment and outcomes.
    El-Dahiyat F; Jairoun AA; Al-Hemyari SS; Shahwan M; Hassan N; Jairoun S; Jaber AAS
    Int J Pharm Pract; 2023 Jun; 31(4):387-395. PubMed ID: 37116892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacists' readiness and willingness to vaccinate the public in United Arab Emirates community pharmacies: A cross-sectional study.
    Thomas D; Abdalla A; Hussein S; Joury J; Elshamy A; Khalifa S; Saleh Z
    F1000Res; 2023; 12():292. PubMed ID: 38774308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergency Contraception Access and Counseling in Metropolitan and Nonmetropolitan Pharmacies in Georgia.
    Stone RH; Gross S; Reardon B; Young HN
    J Pharm Pract; 2023 Jun; 36(3):523-531. PubMed ID: 34881653
    [No Abstract]   [Full Text] [Related]  

  • 9. Naloxone availability in independent community pharmacies in Georgia, 2019.
    Gilbert L; Elliott J; Beasley L; Oranu E; Roth K; Nguyễn J
    Subst Abuse Treat Prev Policy; 2021 Aug; 16(1):63. PubMed ID: 34419089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama.
    Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL
    Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Community pharmacists' attitudes toward providing care and services to patients with severe and persistent mental illness.
    Watkins A; McKee J; Hughes C; Pfeiffenberger T
    J Am Pharm Assoc (2003); 2017; 57(3S):S217-S224.e2. PubMed ID: 28408170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacists' role in harm reduction: a survey assessment of Kentucky community pharmacists' willingness to participate in syringe/needle exchange.
    Goodin A; Fallin-Bennett A; Green T; Freeman PR
    Harm Reduct J; 2018 Jan; 15(1):4. PubMed ID: 29370808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examination of why some community pharmacists do not provide 72-hour emergency prescription drugs to Medicaid patients when prior authorization is not available.
    Shepherd MD
    J Manag Care Pharm; 2013 Sep; 19(7):523-33. PubMed ID: 23964613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia.
    Thornton JD; Lyvers E; Scott VGG; Dwibedi N
    J Am Pharm Assoc (2003); 2017; 57(2S):S12-S18.e4. PubMed ID: 28163027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of pharmacy and pharmacist characteristics on the secondary prevention of cardiovascular disease.
    Puspitasari HP; Aslani P; Krass I
    Int J Clin Pharm; 2015 Oct; 37(5):834-43. PubMed ID: 25964140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer health promotion in Qatar: a survey of community pharmacists' interests and needs.
    El Hajj MS; Hamid Y
    Int J Clin Pharm; 2011 Feb; 33(1):70-9. PubMed ID: 21365398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community Pharmacists' Knowledge and Perceptions of Buprenorphine for Patients with Opioid Use Disorder.
    Tutag Lehr V; Nolan C
    J Addict Med; 2023 Jul-Aug 01; 17(4):e224-e231. PubMed ID: 37579094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient awareness, willingness, and barriers to point-of-care hepatitis C screening in community pharmacy.
    Brewer A; Hanna C; Eckmann L; Schadler A; Divine H
    J Am Pharm Assoc (2003); 2018; 58(4S):S69-S72.e1. PubMed ID: 30006188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A national survey exploring oral healthcare service provision across Australian community pharmacies.
    Freeman CR; Abdullah N; Ford PJ; Taing MW
    BMJ Open; 2017 Sep; 7(9):e017940. PubMed ID: 28963314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fentanyl test strips as an opioid overdose prevention strategy: Findings from a syringe services program in the Southeastern United States.
    Peiper NC; Clarke SD; Vincent LB; Ciccarone D; Kral AH; Zibbell JE
    Int J Drug Policy; 2019 Jan; 63():122-128. PubMed ID: 30292493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.